P=N/A, N=160, Recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2027 --> Dec 2026 | Trial primary completion date: Mar 2027 --> Dec 2026

P1, N=12, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting

When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.

P3, N=52, Not yet recruiting, R-Pharm International, LLC

Although the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial demonstrated reduced lung cancer incidence with interleukin (IL)-1β inhibition, the high number needed to treat (NNT) to prevent lung cancer limits its use in unselected populations...Components of the signature were induced by PM, oncogenic EGFR, or IL-1β, whereas IL-1β inhibition restrained PM-driven KAC expansion and early tumorigenesis. In CANTOS, the signature identified individuals who seemed to benefit more from anti-IL-1β therapy, lowering the NNT threshold and nominating circulating signals of tumor promotion for prevention.

P3, N=1400, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting

P=N/A, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University

CRBN-targeting immunomodulatory drugs (IMiDs), including lenalidomide and pomalidomide, are widely used in hematologic malignancies but are associated with an elevated risk of venous thromboembolism (VTE). Early-onset PE risk is mechanistically linked to vascular endothelial injury and inflammatory signaling, supporting the use of dynamic risk stratification tools (e.g., IMPEDE-VTE score) and early DOAC intervention. Public health policy should integrate molecular insights with real-world surveillance to optimize clinical safety frameworks for oncology patients.

P=N/A, N=160, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting | Trial completion date: Sep 2026 --> Mar 2027 | Trial primary completion date: Sep 2026 --> Mar 2027

Immunomodulatory drugs (IMiDs), including lenalidomide and pomalidomide in combination with proteasome inhibitors, dexamethasone and anti-CD38 monoclonal antibodies, play a central role in the treatment of multiple myeloma (MM) across newly diagnosed and relapsed stages. In this review, we explore current literature on the molecular and immune mechanisms related to the onset of therapeutic resistance. We then suggest ways to overcome resistance and exemplify options for the future, focusing on immunotherapy combinations with IMiDs or CELMoDs and novel agents.

P=N/A, N=5, Not yet recruiting, Novartis Pharmaceuticals

Given the limited antitumor efficacy of IL-1β-targeting agents such as Anakinra and Canakinumab, we focused on IRAK4 as a therapeutic target. RNA-seq revealed enrichment of neutrophil activation signatures and suppression of extracellular matrix (ECM) gene programs. Together, these findings establish a role for the IL-1β/IL1R1/IRAK4 axis in inflammation-driven PSM and peritoneal seeding and ECM regulation in EOC, and demonstrate that IRAK4 inhibition activates antitumor immune responses, providing a therapeutic strategy to block metastatic seeding and improve tumor control.